SABCS 2022 | neoHIP: neoadjuvant HER2-targeted therapy +/- IO with pembrolizumab
Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, provides an overview of the Phase II neoHIP (NCT03747120) trial investigating neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab in in chemo naive patients with invasive HER2-positive breast cancer. As immune checkpoint inhibitors may confer enhanced activity when administered earlier in the course of disease, ICIs administered in the treatment-naive setting may allow for de-escalation of cytotoxic chemotherapy. The primary endpoint is pathological complete response (pCR). This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The neoHIP trial was presented as a trial in progress. So, this is a neoadjuvant study looking at paclitaxel with trastuzumab and pertuzumab plus or minus pembrolizumab. It’s an investigator initiated trial that’s supported by Merck, and the idea is that if you can synergize her two directed therapy with immune therapy, which has been done very successfully in the laboratory, if we can harness that synergy and administer drugs earlier on in the course of the disease, which has been an important lesson that we’ve learned from triple-negative breast cancer, the earlier on that you administer immune therapy, the more likely it is to be successful...
The neoHIP trial was presented as a trial in progress. So, this is a neoadjuvant study looking at paclitaxel with trastuzumab and pertuzumab plus or minus pembrolizumab. It’s an investigator initiated trial that’s supported by Merck, and the idea is that if you can synergize her two directed therapy with immune therapy, which has been done very successfully in the laboratory, if we can harness that synergy and administer drugs earlier on in the course of the disease, which has been an important lesson that we’ve learned from triple-negative breast cancer, the earlier on that you administer immune therapy, the more likely it is to be successful. So, that’s what this study is aimed to ask and answer. Can the addition of pembrolizumab improve pathologic complete response and allow for a backbone that includes only one chemotherapeutic?
Read more...
